↓ Skip to main content

Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung…

Overview of attention for article published in BMC Cancer, December 2018
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (55th percentile)

Mentioned by

googleplus
1 Google+ user
reddit
1 Redditor

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
69 Mendeley
Title
Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
Published in
BMC Cancer, December 2018
DOI 10.1186/s12885-018-5146-3
Pubmed ID
Authors

Yasuhiro Tsutani, Yoshihiro Miyata, Takeshi Masuda, Kazunori Fujitaka, Mihoko Doi, Yoshikazu Awaya, Shoichi Kuyama, Soichi Kitaguchi, Kazuhiro Ueda, Noboru Hattori, Morihito Okada

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 69 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 69 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 7 10%
Student > Master 6 9%
Student > Doctoral Student 5 7%
Researcher 4 6%
Other 4 6%
Other 15 22%
Unknown 28 41%
Readers by discipline Count As %
Medicine and Dentistry 20 29%
Biochemistry, Genetics and Molecular Biology 7 10%
Nursing and Health Professions 4 6%
Psychology 3 4%
Pharmacology, Toxicology and Pharmaceutical Science 2 3%
Other 4 6%
Unknown 29 42%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 December 2018.
All research outputs
#15,027,561
of 23,117,738 outputs
Outputs from BMC Cancer
#3,719
of 8,390 outputs
Outputs of similar age
#250,646
of 436,845 outputs
Outputs of similar age from BMC Cancer
#78
of 201 outputs
Altmetric has tracked 23,117,738 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,390 research outputs from this source. They receive a mean Attention Score of 4.3. This one has gotten more attention than average, scoring higher than 50% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 436,845 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 201 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.